General Statement of Disclosure:

EQUITY INTERESTS/STOCK OPTIONS: Pfizer Inc(MODEST), Medtronic(MODEST), Vertex Pharmaceuticals(SIGNIFICANT) RESEARCH/RESEARCH GRANTS: Amgen Inc.(SIGNIFICANT), Bayer(SIGNIFICANT), ARCA biopharma, Inc.(SIGNIFICANT), NovoNordisk(SIGNIFICANT), Merck & Co., Inc.(SIGNIFICANT), Wraser(SIGNIFICANT), AstraZeneca Pharmaceuticals(SIGNIFICANT), Better Therapeutics(SIGNIFICANT), ARCA(SIGNIFICANT), Abbott Laboratories(SIGNIFICANT), Agios Pharmaceuticals(SIGNIFICANT), Alexion Pharma(SIGNIFICANT), Angionetics(SIGNIFICANT), Atentiv(SIGNIFICANT), Audentes(SIGNIFICANT), Bristol-Myers Squibb Company (SIGNIFICANT), Cardiol Therapeutics(SIGNIFICANT), CellResearch(SIGNIFICANT), Cook Regentec(SIGNIFICANT), CSL Behring (SIGNIFICANT), Eidos Therapeutics(SIGNIFICANT), Esperion(SIGNIFICANT), EverlyWell(SIGNIFICANT), Faraday Pharmaceuticals(SIGNIFICANT), Fortress Biotech(SIGNIFICANT), Heartflow(SIGNIFICANT), Insmed(SIGNIFICANT), Kowa Research(SIGNIFICANT), EP Trading Company(SIGNIFICANT), Lexicon(SIGNIFICANT), Pfizer Inc(SIGNIFICANT), Alnylam(SIGNIFICANT), Array(SIGNIFICANT), PPD Development(SIGNIFICANT), Prothena Biosciences(SIGNIFICANT), Regeneron(SIGNIFICANT), University of Colorado(SIGNIFICANT), Moderna(SIGNIFICANT), Regio Biosciences(SIGNIFICANT), Sanifit(SIGNIFICANT), Sanofi-Aventis(SIGNIFICANT), Stealth BioTherapeutics(SIGNIFICANT), Brigham and Women's Hospital(SIGNIFICANT), Worldwide Clinical Trials(SIGNIFICANT), Yale Cardiovascular Research Group(SIGNIFICANT), PhaseBio(SIGNIFICANT), Janssen Pharmaceuticals, Inc(SIGNIFICANT) OTHER FINANCIAL BENEFIT: AHA(SIGNIFICANT), Anthos Therapeutics(SIGNIFICANT), Cambrian Biopharma(SIGNIFICANT), EPG Communications(MODEST), Epizon Pharma(SIGNIFICANT), NIH(SIGNIFICANT), Novartis Corporation(SIGNIFICANT), St. Luke's Hospital of Kansas City(SIGNIFICANT), Silence Therapeutics(SIGNIFICANT), Thrombosis Research Institute(SIGNIFICANT), University of Pittsburgh(SIGNIFICANT), VarmX(SIGNIFICANT), Cleerly(SIGNIFICANT)

View Full Disclosure